217 related articles for article (PubMed ID: 32379987)
21. Successes and limitations of targeted therapies in renal cell carcinoma.
Pracht M; Berthold D
Prog Tumor Res; 2014; 41():98-112. PubMed ID: 24727990
[TBL] [Abstract][Full Text] [Related]
22. Basic research in kidney cancer.
Oosterwijk E; Rathmell WK; Junker K; Brannon AR; Pouliot F; Finley DS; Mulders PF; Kirkali Z; Uemura H; Belldegrun A
Eur Urol; 2011 Oct; 60(4):622-33. PubMed ID: 21741760
[TBL] [Abstract][Full Text] [Related]
23. Targeted therapies for renal cell carcinoma.
Posadas EM; Limvorasak S; Figlin RA
Nat Rev Nephrol; 2017 Aug; 13(8):496-511. PubMed ID: 28691713
[TBL] [Abstract][Full Text] [Related]
24. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
Tang PA; Vickers MM; Heng DY
Hematol Oncol Clin North Am; 2011 Aug; 25(4):871-91. PubMed ID: 21763972
[TBL] [Abstract][Full Text] [Related]
25. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
[TBL] [Abstract][Full Text] [Related]
26. Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma.
Wang R; Zheng J; Shao X; Ishii Y; Roy A; Bello A; Lee R; Zhang J; Wind-Rotolo M; Feng Y
J Immunother Cancer; 2019 Dec; 7(1):348. PubMed ID: 31829287
[TBL] [Abstract][Full Text] [Related]
27. Biomarkers for immunotherapy in urological cancers.
Gust KM; Resch I; D'Andrea D
Curr Opin Urol; 2018 Jan; 28(1):25-28. PubMed ID: 29120910
[TBL] [Abstract][Full Text] [Related]
28. Novel molecular signatures and potential therapeutics in renal cell carcinomas: Insights from a comparative analysis of subtypes.
Caliskan A; Andac AC; Arga KY
Genomics; 2020 Sep; 112(5):3166-3178. PubMed ID: 32512143
[TBL] [Abstract][Full Text] [Related]
29. Molecular subtypes as potential biomarkers in renal cell carcinoma.
Hage Chehade C; Agarwal N
Cancer Cell; 2024 May; 42(5):736-738. PubMed ID: 38670092
[TBL] [Abstract][Full Text] [Related]
30. Investigational MET inhibitors to treat Renal cell carcinoma.
Nandagopal L; Sonpavde GP; Agarwal N
Expert Opin Investig Drugs; 2019 Oct; 28(10):851-860. PubMed ID: 31554440
[No Abstract] [Full Text] [Related]
31. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
Abdelaziz A; Vaishampayan U
Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
[TBL] [Abstract][Full Text] [Related]
32. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
[TBL] [Abstract][Full Text] [Related]
33. The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy.
Nakaigawa N; Kondo K; Ueno D; Namura K; Makiyama K; Kobayashi K; Shioi K; Ikeda I; Kishida T; Kaneta T; Minamimoto R; Tateishi U; Inoue T; Yao M
BMC Cancer; 2017 Jan; 17(1):39. PubMed ID: 28068944
[TBL] [Abstract][Full Text] [Related]
34. A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma.
Gremel G; Djureinovic D; Niinivirta M; Laird A; Ljungqvist O; Johannesson H; Bergman J; Edqvist PH; Navani S; Khan N; Patil T; Sivertsson Å; Uhlén M; Harrison DJ; Ullenhag GJ; Stewart GD; Pontén F
BMC Cancer; 2017 Jan; 17(1):9. PubMed ID: 28052770
[TBL] [Abstract][Full Text] [Related]
35. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.
Golshayan AR; Brick AJ; Choueiri TK
Future Oncol; 2008 Feb; 4(1):85-92. PubMed ID: 18241003
[TBL] [Abstract][Full Text] [Related]
36. A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma.
Funakoshi T; Lee CH; Hsieh JJ
Cancer Treat Rev; 2014 May; 40(4):533-47. PubMed ID: 24398141
[TBL] [Abstract][Full Text] [Related]
37. The emerging role of nuclear factor kappa B in renal cell carcinoma.
Morais C; Gobe G; Johnson DW; Healy H
Int J Biochem Cell Biol; 2011 Nov; 43(11):1537-49. PubMed ID: 21854869
[TBL] [Abstract][Full Text] [Related]
38. Are primary renal cell carcinoma and metastases of renal cell carcinoma the same cancer?
Semeniuk-Wojtaś A; Stec R; Szczylik C
Urol Oncol; 2016 May; 34(5):215-20. PubMed ID: 26850779
[TBL] [Abstract][Full Text] [Related]
39. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
[TBL] [Abstract][Full Text] [Related]
40. Emerging critical role of molecular testing in diagnostic genitourinary pathology.
Netto GJ; Cheng L
Arch Pathol Lab Med; 2012 Apr; 136(4):372-90. PubMed ID: 22458900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]